Efficacy and Safety of Compound Kushen Injection Used for Peritoneal Perfusion on Patients with Malignant Ascites
10.3969/j.issn.1005-5304.2015.02.009
- VernacularTitle:复方苦参注射液腹腔灌注治疗恶性腹水疗效及安全性观察
- Author:
Jiaqi LIU
- Publication Type:Journal Article
- Keywords:
malignant ascites;
compound Kushen Injection;
cisplatin;
peritoneal perfusion
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2015;(2):28-30
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of compound Kushen Injection in the patients with malignant ascites. Methods Totally 139 patients with malignant ascites were randomly divided into treatment group and control group. 30 mL compound Kushen Injection was given to the treatment group, and 100 mg cisplatin was given to the control group through peritoneal perfusion once a week, for 3 weeks. The changes of urine volume, abdominal perimeter, blood-Rt, function of liver and kidney, and gastrointestinal reaction were detected before and after treatment, with a purpose to evaluate the total efficacy and safety. Results The total effective rate was 80.56% (58/72) in treatment group, and 86.57% (58/67) in the control group, without significant difference between the two groups. The incidences of bone marrow suppression, liver and kidney damage, and nausea and vomiting of gastrointestinal reaction were lower in the treatment group than the control group. Conclusion The effects of compound Kushen Injection and cisplatin have equal efficacy for the treatment of malignant ascites, but the former was superior to the latter on safety.
